Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Exchange | Industry | Zen Rating | Market Cap | Price | 1d % | EBITDA | P/E | D/E | Country | DD Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | NASDAQ | Biotechnology | $12.56B | $116.23 | 1.93% | $7.85M | 219.30x | 0.26 | United States | ||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | NASDAQ | Biotechnology | $3.16B | $25.16 | -0.51% | $45.39M | 119.81x | 1.22 | United States | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | NASDAQ | Biotechnology | $29.40B | $219.72 | -4.96% | $1.18B | 36.02x | 3.11 | United States | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | NASDAQ | Biotechnology | $5.91B | $75.79 | 0.76% | $119.96M | 70.83x | 0.37 | Bermuda | ||
| VCEL | VERICEL CORP | NASDAQ | Biotechnology | $2.06B | $40.15 | 1.80% | $44.05M | 83.65x | 0.36 | United States | ||
| RPRX | ROYALTY PHARMA PLC | NASDAQ | Biotechnology | $32.87B | $57.16 | -0.82% | $1.18B | 30.40x | 1.03 | United States | ||
| KRYS | KRYSTAL BIOTECH INC | NASDAQ | Biotechnology | $9.54B | $322.28 | -0.93% | $233.29M | 38.97x | 0.10 | United States | ||
| HALO | HALOZYME THERAPEUTICS INC | NASDAQ | Biotechnology | $12.47B | $109.86 | 2.73% | $718.44M | 30.86x | 16.96 | United States | ||
| ZVRA | ZEVRA THERAPEUTICS INC | NASDAQ | Biotechnology | $593.24M | $9.99 | -1.87% | $77.33M | 10.52x | 0.39 | United States | ||
| TGTX | TG THERAPEUTICS INC | NASDAQ | Biotechnology | $8.31B | $54.29 | 1.25% | $139.21M | 17.63x | 1.71 | United States | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | NASDAQ | Biotechnology | $11.07B | $57.18 | -2.16% | $385.69M | 150.47x | 0.85 | United States | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | NASDAQ | Biotechnology | $15.30B | $235.67 | 1.14% | $1.62B | 15.44x | 1.31 | Ireland | ||
| MDXG | MIMEDX GROUP INC | NASDAQ | Biotechnology | $669.04M | $4.59 | -1.08% | $22.81M | 114.75x | 0.30 | United States | ||
| EXEL | EXELIXIS INC | NASDAQ | Biotechnology | $14.47B | $58.39 | 0.78% | $1.09B | 17.75x | 0.35 | United States | ||
| ADMA | ADMA BIOLOGICS INC | NASDAQ | Biotechnology | $2.18B | $9.72 | -2.11% | $232.99M | 13.50x | 0.68 | United States | ||
| LGND | LIGAND PHARMACEUTICALS INC | NASDAQ | Biotechnology | $6.04B | $302.96 | 0.07% | $278.98M | 30.09x | 1.26 | United States | ||
| VRTX | VERTEX PHARMACEUTICALS INC | NASDAQ | Biotechnology | $127.93B | $504.73 | -0.40% | $5.50B | 29.12x | 0.35 | United States | ||
| UTHR | UNITED THERAPEUTICS CORP | NASDAQ | Biotechnology | $23.23B | $541.70 | -5.19% | $1.68B | 17.91x | 0.13 | United States | ||
| TECH | BIO-TECHNE CORP | NASDAQ | Biotechnology | $11.35B | $72.40 | 0.00% | $347.67M | 61.88x | 0.23 | United States | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | NASDAQ | Biotechnology | $2.31B | $39.64 | 0.18% | $280.01M | 12.62x | 0.37 | United States | ||
| REGN | REGENERON PHARMACEUTICALS INC | NASDAQ | Biotechnology | $75.69B | $735.20 | 0.05% | $5.75B | 17.53x | 0.32 | United States | ||
| VCYT | VERACYTE INC | NASDAQ | Biotechnology | $3.68B | $45.81 | 3.67% | $139.68M | 31.81x | 0.07 | United States | ||
| SPRO | SPERO THERAPEUTICS INC | NASDAQ | Biotechnology | $69.30M | $1.19 | -5.56% | $7.64M | 8.50x | 0.19 | United States | ||
| INCY | INCYTE CORP | NASDAQ | Biotechnology | $23.37B | $115.30 | -1.57% | $2.07B | 14.20x | 0.24 | United States |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.